CEO and co-founder Del Smith designed AVA to solve a persistent blind spot in clinical development. While organizations often possess granular data on individual diagnoses and site proximity, they frequently lack insight into the community signals—such as local belief systems, trust levels, and economic pressures—that dictate patient participation. By synthesizing more than 100 million behavioral and social determinants of health data points, the platform aims to shift industry strategy from reactive troubleshooting to proactive engagement.
Acclinate Targets Clinical Trial Gaps with New Community Intelligence Tool
Four years after winning DPHARM Idol for its work on trial diversity, Birmingham-based Acclinate is returning to the conference to unveil AVA. The new platform leverages over six years of proprietary data to help pharmaceutical companies predict patient behavior and address community-level barriers before enrollment stalls.
Predicting Patient Engagement
AVA functions as the intelligence layer for Acclinate’s broader ecosystem, working in tandem with the company’s existing activation engine, NOWINCLUDED. The platform targets the specific "why" behind enrollment failures, helping teams identify where barriers are emerging and which interventions will yield measurable results. For Smith, the goal is to transform how the industry views underrepresented communities, moving beyond simple demographic tracking toward a model that anticipates patient needs. By integrating geographic, site, and engagement context, Acclinate intends to provide enterprise-level decision support for clinical research, therapeutic strategy, and population health initiatives.
Comments (0)
No comments yet. Be the first!